ClinicalTrials.gg
CompletedNCT01020279Updated Jun 28, 2010

Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise

A Phase 1 interventional study of Celecoxib, Ketoprofen and Ketoprofen in Musculoskeletal Pain, sponsored by X-pert Med GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-28.

Primary conditionMyalgiaRegistry: Musculoskeletal PainReclassifiedWhy we changed it
Registry
Musculoskeletal Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Myalgia
Why
  1. The study's title name Myalgia, a narrower term within Musculoskeletal Pain.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by X-pert Med GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Myalgia with a site in Germany — 1 open to participants now, 1 under way, none of them phase 3. Myalgia · Germany.

Started
2009
the only one that year
Phase 1
2 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
2 of 10
X-pert Med GmbH

Among the 10 studies in Myalgia with a site in Germany, this one is the only one that started in 2009, is one of 2 in phase 1, and was the 4th registered.

Myalgia

256 studies on the registry are indexed under Myalgia; 46 are open to participants now.

Browse Myalgia studies →

Open to participants now

1 of the 10 studies in Myalgia with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 27 Myalgia studies recruiting now, 6 (22%) set no upper age limit and 20 (74%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Myalgia with a site in Germany, or all of them as a file.
02

Study summary

  1. Comparison of the effect of ketoprofen Transfersome® gel (KTG) to placebo gel (PG) on muscle pain of the calf caused by eccentric contractions
  2. Comparison of the effect of KTG to celecoxib (CE) on muscle pain of the calf caused by eccentric contractions
  3. Comparison of the effect of celecoxib (CE) to oral placebo (OP) on muscle pain of the calf caused by eccentric contractions
03

Conditions studied

  • Musculoskeletal Pain

Browse trials for

Keywords

  • muscle pain
  • model
04

In context

Myalgia Reclassified

256 studies on the registry are indexed under Myalgia; 46 are open to participants now.

This study's enrollment of 82 is above the median of 44 across 216 interventional studies indexed under Myalgia.

Browse Myalgia studies →

Lead sponsor

X-pert Med GmbH is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Myalgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Musculoskeletal Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated prior to participation
  • Subjects in good health as determined by the Investigator
  • Age 18-55
  • Willing to abstain from any physical therapy, hard physical work, exercise or sauna during the study observation period (Screening to Final Visit)
  • For females, subjects of (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate (defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are allowed in this study. Female subjects, who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) are also allowed for participation

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study within the last 30 days and during the study
  • Subjects who are inmates of psychiatric wards, prisons, or other state institutions
  • Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
  • Pregnancy or lactation
  • Alcohol or drug abuse
  • within the past 2 years with the exception of in situ removal of basal cell carcinoma
  • Skin lesions, dermatological diseases or tattoo in the treatment areas
  • Known or allergy (including photoallergy) to NSAID´s including celecoxib, sulfonamides and ingredients used in pharmaceutical products and cosmetics including galactose
  • Varicosis, thrombophlebitis and other vascular disorders of the lower extremities
  • Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the musculo-skeletal system of the lower limbs
  • Pain conditions which might interfere with pain rating during the study, e.g. neuropathic pain
  • Significant neurological or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately (e.g. Alzheimer's disease or schizophrenia or other psychosis), that in the investigator's opinion may affect efficacy or safety assessments or may compromise subject safety during the study
  • Systemic lupus erythematodes, mixed connective tissue disease
  • Major heart disease / uncontrollable hypertension
  • Peripheral arterial disease and/or cerebrovascular disease
  • History of stroke or myocardial infarction
  • \< 30 ml/min
  • and/or AST levels ≥ 5 times the
  • including asthma bronchiale
  • Coagulopathy or bleeding diathesis, or concomitant use of anticoagulants including low dose aspirin
  • History of pancreatitis or peptic ulcers
  • Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)
  • Reflux esophagitis requiring treatment
  • Any other analgesic therapy including cough and cold drugs containing analgesic properties as well as any other substance used for the treatment of pain during the study observation period (Screening to final Visit)
  • Any other drug that might alter pain perception like CNS active drugs
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
82 participants (actual)

Study arms

  • Other
    Parallel Group A

    Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)

    Drug: Celecoxib, Ketoprofen

  • Other
    Parallel Group B

    oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)

    Drug: Ketoprofen

Interventions

  • DrugCelecoxib, Ketoprofen

    Drug pages: Celecoxib · Ketoprofen

    Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Celecoxib, 200 mg, one capsule b.i.d.

  • Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d

07

What researchers measure

Primary outcomes

  1. Pain during muscle contraction

    Time frame: Day 7

Secondary outcomes

  1. Pain during rest

    Time frame: Day 7

  2. Surface temperature

    Time frame: Day 7

  3. Volume of the lower leg

    Time frame: Day 7

08

Study locations

1 site
  • X-pert Med GmbH
    Jena, 07745, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2009
First posted
Nov 25, 2009
Start
Oct 2009
CompletionActual
Jan 2010
Last update
Jun 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01020279
Lead sponsor
X-pert Med GmbH
First posted
Nov 25, 2009
Start date
Oct 2009
Completion
Jan 2010
Last update
Jun 28, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Ketoprofen

Start the discussion